A Phase 4 interventional study of Intravenous/Subcutaneous Treprostinil; Oral Treprostinil in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Completed at 11 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-08-07.
Sponsored by United Therapeutics · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 18th largest by enrollment, is one of 5 that started in 2019, is one of 14 in phase 4, and was the 34th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:
Liquidia Technologies, Inc. · Sites in United States
Ages 18–80
University of Arizona · Sites in United States
Ages 18+
Shanghai Zhongshan Hospital
Ages 18–75
By country, each count listing its studies:
treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2019.
This study's enrollment of 36 is close to the median of 40 across 477 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 32 across the 44 interventional studies. Of the 32 that completed or were terminated, 20 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
51 studies in Pulmonary Arterial Hypertension by United Therapeutics: 1 open now, 3 under way, 1 of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 51 studies in Pulmonary Arterial Hypertension by United Therapeutics, this one is the 20th largest by enrollment of the 45 interventional ones that give a count, is one of 5 that started in 2019, is one of 11 in phase 4, and was the 43rd registered.
United Therapeutics’s Pulmonary Arterial Hypertension studies by the year they started, since 2002.
1 of the studies testing treprostinil in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759804Liquidia Technologies, Inc.A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, from their registry updates:
Among United Therapeutics’s 51 in Pulmonary Arterial Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a multicenter, open-label study to evaluate the dose of Orenitram® (treprostinil) Extended Release Tablets achieved at 16 weeks after a short-term course of Remodulin® (treprostinil) Injection in subjects with pulmonary arterial hypertension (PAH).
Subjects were initiated on subcutaneous (SC) or intravenous (IV) treprostinil and titrated to a dose that improved the symptoms of PAH while minimizing excessive pharmacologic effects. After achieving a minimum SC/IV treprostinil dose of 20 ng/kg/min, subjects began a transition to oral treprostinil at the Transition Visit, which occurred at the Week 2, 4, or 8 study visit. After the Transition Visit, oral treprostinil titration continued through Week 16 to reach the maximum tolerated dose (MTD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects who agreed to follow the specified precautions to avoid pregnancy as follows:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects began Remodulin at 2 ng/kg/min subcutaneously (SC) or intravenously (IV) and were optimized to their maximum tolerated dose (MTD) of Remodulin. Subjects were then transitioned to Orenitram XR tablets (oral) based upon their Remodulin dose. Subjects were optimized on Orenitram therapy to a MTD. There were no maximum Remodulin or Orenitram doses specified during the study.
Drug: Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
Drug page: Treprostinil
Short-term course of IV or SC treprostinil continuous infusion followed by transition to oral treprostinil extended-release (XR) tablets taken 3 times daily (TID)
Also known as: Remodulin, Orenitram
Number of Subjects Achieving Oral Treprostinil Dose
The number of subjects that achieved an oral treprostinil dose of ≥4 mg TID (or a total daily dose \[TDD\] of 12 mg) at Week 16 (or a dose of ≥0.057 mg/kg TID \[TDD of 0.171 mg/kg\] for subjects \<70 kg).
Time frame: Assessed at Week 16
Change in 6-minute Walk Distance (6MWD)
The 6-Minute Walk Test (6MWT) is used to measure exercise ability in patients with chronic respiratory diseases. The distance walked on a predetermined course over 6 minutes was recorded.
Time frame: From Baseline to Week 16
Change in Borg Dyspnea Score
The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6MWT. Scores range from 0 (no shortness of breath) to 10 (worst shortness of breath you have ever had).
Time frame: From Baseline to Week 16
Number of Subjects With Changes in WHO FC
WHO FC ranges from I (subjects with PH but without resulting limitation of physical activity) to IV (subjects with PH with inability to carry out any physical activities without symptoms). A lower WHO FC was considered "improved"; a higher WHO FC was considered "worsened."
Time frame: From Baseline to Week 16
Change in Serum N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Levels
NT-proBNP is a hormone produced by the heart. NT-proBNP concentration is associated with changes in right heart morphology and function. The main purpose of NT-proBNP testing is to see if the blood levels of this protein are within the expected range for a healthy person. Normal levels of NT-proBNP are less than 125 pg/mL for people under 75 years old and less than 450 pg/mL for people over age 75. NT-proBNP levels over 900 pg/mL may be a sign of heart failure. The higher the level, the more serious the condition.
Time frame: From Baseline to Week 16
Change in Echocardiogram Parameters (Change in Cardiac Output)
ECHOs provide information regarding cardiac structure and function. Cardiac output was summarized at each time point listed.
Time frame: At Baseline and Week 16
Change in Echocardiogram Parameters (Heart Rate)
ECHOs provide information regarding cardiac structure and function. Heart rate was summarized at each time point listed.
Time frame: At Baseline and Week 16
Change in Echocardiogram Parameters (Left Ventricular Outflow Track Dimension)
ECHOs provide information regarding cardiac structure and function. Left ventricular outflow track (LVOT) dimension was summarized at each time point listed.
Time frame: At Baseline and Week 16
Change in Echocardiogram Parameters (LVOT Velocity Time Integral)
ECHOs provide information regarding cardiac structure and function. LVOT velocity time integral was summarized at each time point listed.
Time frame: At Baseline and Week 16
Change in Echocardiogram Parameters (LV Diameter)
ECHOs provide information regarding cardiac structure and function. LV diameter was summarized at each time point listed.
Time frame: At Baseline and Week 16
Change in Echocardiogram Parameters (LV Eccentricity Index [Diastole])
ECHOs provide information regarding cardiac structure and function. LV Eccentricity Index (Diastole) was summarized at each time point listed. Diastole LV Eccentricity Index is measured during ECHOs to assess how much the shape of the LV deviates from normal while the heart is relaxing (full of blood prior to contraction). A lower Diastole LV Eccentricity Index indicates that the LV is closer to a normal shape during diastole. A higher Diastole LV Eccentricity Index indicates that the LV is more elongated/stretched during diastole, indicating potential heart problems. There is no theoretical minimum or maximum value for the index range.
Time frame: At Baseline and Week 16
Change in Echocardiogram Parameters (LV Eccentricity Index [Systole])
ECHOs provide information regarding cardiac structure and function. LV Eccentricity Index (Systole) was summarized at each time point listed. Systole LV Eccentricity Index is measured during ECHOs to assess how much the shape of the LV deviates from normal while the heart is contracting (pumping blood to the body). A lower Systole LV Eccentricity Index indicates that the LV is closer to a normal shape during systole. A higher Systole LV Eccentricity Index indicates that the LV is more elongated/stretched during systole, indicating potential heart problems. There is no theoretical minimum or maximum value for the index range.
Time frame: At Baseline and Week 16
Change in Echocardiogram Parameters (Pulmonary Valve Acceleration Time)
ECHOs provide information regarding cardiac structure and function. Pulmonary valve acceleration time was summarized at each time point listed.=.
Time frame: At Baseline and Week 16
Change in Echocardiogram Parameters (RV/LV Ratio)
ECHOs provide information regarding cardiac structure and function. RV/LV (diastole) ratio was summarized at each time point listed. RV/LV Ratio is the ratio of right ventricular to left ventricular diameter. A normal RV/LV Ratio is 0.6 to 1.0. When the ratio exceeds 1.0 it is indicative of high pulmonary artery pressure or right ventricular hypertrophy.
Time frame: At Baseline and Week 16
Change in Echocardiogram Parameters (Right Atrial Area)
ECHOs provide information regarding cardiac structure and function. Right atrial area was summarized at each time point listed.
Time frame: At Baseline and Week 16
Change in Echocardiogram Parameters (RV Diameter)
ECHOs provide information regarding cardiac structure and function. RV diameter was summarized at each time point.
Time frame: At Baseline and Week 16
Change in Echocardiogram Parameters (RV Free Wall Strain)
ECHOs provide information regarding cardiac structure and function. RV free wall strain was summarized at each time point listed .
Time frame: At Baseline and Week 16
Change in Echocardiogram Parameters (RV Myocardial Performance Index)
ECHOs provide information regarding cardiac structure and function. RV myocardial performance index (MPI) was summarized at each time point listed. RV MPI is a measurement used to assess RV systolic function in patients with PH. MPI correlates with pulmonary arterial pressure. Normal MPI is approximately 0.35. Higher MPI values indicate higher pulmonary arterial pressure.
Time frame: At Baseline and Week 16
Change in Echocardiogram Parameters (Tricuspid Annular Plane Systolic Excursion)
ECHOs provide information regarding cardiac structure and function. Tricuspid annular plane systolic excursion was summarized at each time point listed.
Time frame: At Baseline and Week 16
Change in PAH Symptom Score
PAH symptoms included fatigue, dyspnea, lower extremity edema, dizziness, syncope, chest pain, and orthopnea. Symptoms were scored (Grades 0 \[none\], 1 \[mild\], 2 \[moderate\], to 3 \[severe\]) except for syncope (0 \[No\], 1 \[Infrequent; 1 episode\], 2 \[Somewhat frequent; 2 to 3 episodes\], and 3 \[Often; \>4 episodes). A lower score was considered "improved"; a higher score was considered "worsened."
Time frame: At Baseline and Week 16
Change in Patient-reported Outcomes (Health-related Quality of Life)
The Health-related Quality of Life in Pulmonary Hypertension Questionnaire (emPHasis-10) is a 10-question questionnaire used during clinical assessments that measures quality of life by the patients participating in the study. The patients graded their response to each of the 10 health-related questions on a scale of 0 to 5 based on how they were feeling that day. The most favorable score for each question is 0, and the least favorable score for each question is 5. A total score was then summed for each subject based on their responses to the 10 questions. The lower the total score was (best possible total score was 0), the less living with PH was negatively affecting the quality of the patient's life. The higher the total score (worst possible score was 50), the more living with PH was negatively affecting the quality of the patient's life.
Time frame: At Baseline and Week 16
Change in Treatment Satisfaction
The Treatment Satisfaction Questionnaire for Medication (TSQM) is a 14-question questionnaire that measures the level of satisfaction or dissatisfaction patients have with their study medication in 4 areas: effectiveness (3 questions), side effects (5 questions), convenience (3 questions), and global satisfaction (3 questions). With the exception of the first side effects question (a yes or no question), all items have 5 or 7 responses which are scored from 1 (least satisfied) to 5 or 7 (most satisfied). A total score is then summed for each domain on the following scales: effectiveness 1-21, side effects 1-20, convenience 1-21, and global satisfaction 1-17. Lower total scores in each domain indicate dissatisfaction with the study medication and higher total scores indicate satisfaction.
Time frame: At Baseline and Week 16
Improvement From Baseline in Clinical Risk Category
6MWD low risk: \>440 m, intermediate risk: 165-440 m, high risk: \<165 m; NT-proBNP low risk: \<300 ng/L, intermediate risk: 300-1400 ng/L, high risk: \>1400 ng/L; WHO FC: low risk: I or II, intermediate risk: III, high risk: IV; and Right Atrial Area: low risk: \<18 cm², intermediate risk: 18-26 cm², high risk: \>26 cm². Moving from a higher risk category to a low risk category was considered "improved;" moving from a lower risk category to a higher risk category was considered "worsened."
Time frame: At Baseline and Week 16
Achievement of Low Risk Category in Clinical Parameters
Low risk categories for the 4 selected parameters were: 6MWD \>440 m, serum NT-proBNP \<300 ng/L, WHO FC I or II, and right atrial area \<18cm². The rows of the table indicate the count of participants that were in the low risk category for the parameter at Week 16.
Time frame: At Week 16
Overall Achievement
The percentage of subjects that ended the study in achievement Class 1 (either achieved an Orenitram dose of ≥4 mg TID \[or TDD of 12 mg\] at Week 16 or a dose of ≥0.057 mg/kg TID \[or a TDD of 0.171 mg/kg\] for subjects \<70 kg), Class 2 (achieved a prescribed Orenitram dose ≥2 mg TID and \<4 mg TID \[or a TDD ≥6 mg and \<12 mg\] at specific visit, with at least 2 of the following 3 clinical parameters: 6MWD increase by ≥10% or ≥30 m from baseline, serum NT-proBNP reduction \>30% from baseline, or WHO FC I or II), or Class 3 (were not Class 1 or Class 2, or with class undetermined).
Time frame: At Week 16
Transition and Maintenance of Orenitram Therapy
The percentage of subjects that transitioned to oral treprostinil at any dose and were maintained on therapy at Week 16 (considered a "successful" result).
Time frame: At Week 16
| Milestone | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Started | 35 |
| Completed | 28 |
| Not completed | 7 |
| Withdrew: Adverse event | 2 |
| Withdrew: Death | 1 |
| Withdrew: Physician decision | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Protocol violation | 2 |
The number of subjects that achieved an oral treprostinil dose of ≥4 mg TID (or a total daily dose \[TDD\] of 12 mg) at Week 16 (or a dose of ≥0.057 mg/kg TID \[TDD of 0.171 mg/kg\] for subjects \<70 kg).
| Participants | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Number of Subjects Achieving Oral Treprostinil Dose | 23 |
The 6-Minute Walk Test (6MWT) is used to measure exercise ability in patients with chronic respiratory diseases. The distance walked on a predetermined course over 6 minutes was recorded.
| meters | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Change in 6-minute Walk Distance (6MWD) | 25.00 (-210.0 to 112.0) |
The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6MWT. Scores range from 0 (no shortness of breath) to 10 (worst shortness of breath you have ever had).
| score on a scale | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Change in Borg Dyspnea Score | -1.00 (-5.0 to 4.0) |
WHO FC ranges from I (subjects with PH but without resulting limitation of physical activity) to IV (subjects with PH with inability to carry out any physical activities without symptoms). A lower WHO FC was considered "improved"; a higher WHO FC was considered "worsened."
| Participants | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Improved | 19 |
| Worsened | 1 |
| No Change | 8 |
NT-proBNP is a hormone produced by the heart. NT-proBNP concentration is associated with changes in right heart morphology and function. The main purpose of NT-proBNP testing is to see if the blood levels of this protein are within the expected range for a healthy person. Normal levels of NT-proBNP are less than 125 pg/mL for people under 75 years old and less than 450 pg/mL for people over age 75. NT-proBNP levels over 900 pg/mL may be a sign of heart failure. The higher the level, the more serious the condition.
| ng/L | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Change in Serum N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Levels | -134.0 (-3896 to 556) |
ECHOs provide information regarding cardiac structure and function. Cardiac output was summarized at each time point listed.
| L/min | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Change in Echocardiogram Parameters (Change in Cardiac Output) | 0.55 (-1.7 to 3.1) |
ECHOs provide information regarding cardiac structure and function. Heart rate was summarized at each time point listed.
| beats/min | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Change in Echocardiogram Parameters (Heart Rate) | 1.50 (-17.0 to 23.0) |
ECHOs provide information regarding cardiac structure and function. Left ventricular outflow track (LVOT) dimension was summarized at each time point listed.
| mm | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Change in Echocardiogram Parameters (Left Ventricular Outflow Track Dimension) | 0.42 (-1.1 to 2.6) |
ECHOs provide information regarding cardiac structure and function. LVOT velocity time integral was summarized at each time point listed.
| cm | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Change in Echocardiogram Parameters (LVOT Velocity Time Integral) | 0.93 (-6.8 to 7.7) |
ECHOs provide information regarding cardiac structure and function. LV diameter was summarized at each time point listed.
| mm | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Change in Echocardiogram Parameters (LV Diameter) | 3.52 (-4.4 to 14.1) |
ECHOs provide information regarding cardiac structure and function. LV Eccentricity Index (Diastole) was summarized at each time point listed. Diastole LV Eccentricity Index is measured during ECHOs to assess how much the shape of the LV deviates from normal while the heart is relaxing (full of blood prior to contraction). A lower Diastole LV Eccentricity Index indicates that the LV is closer to a normal shape during diastole. A higher Diastole LV Eccentricity Index indicates that the LV is more elongated/stretched during diastole, indicating potential heart problems. There is no theoretical minimum or maximum value for the index range.
| Eccentricity Index | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Change in Echocardiogram Parameters (LV Eccentricity Index [Diastole]) | 0.04 (-0.3 to 0.3) |
ECHOs provide information regarding cardiac structure and function. LV Eccentricity Index (Systole) was summarized at each time point listed. Systole LV Eccentricity Index is measured during ECHOs to assess how much the shape of the LV deviates from normal while the heart is contracting (pumping blood to the body). A lower Systole LV Eccentricity Index indicates that the LV is closer to a normal shape during systole. A higher Systole LV Eccentricity Index indicates that the LV is more elongated/stretched during systole, indicating potential heart problems. There is no theoretical minimum or maximum value for the index range.
| Eccentricity Index | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Change in Echocardiogram Parameters (LV Eccentricity Index [Systole]) | 0.09 (-1.0 to 0.7) |
ECHOs provide information regarding cardiac structure and function. Pulmonary valve acceleration time was summarized at each time point listed.=.
| msec | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Change in Echocardiogram Parameters (Pulmonary Valve Acceleration Time) | 4.43 (-22.0 to 41.2) |
ECHOs provide information regarding cardiac structure and function. RV/LV (diastole) ratio was summarized at each time point listed. RV/LV Ratio is the ratio of right ventricular to left ventricular diameter. A normal RV/LV Ratio is 0.6 to 1.0. When the ratio exceeds 1.0 it is indicative of high pulmonary artery pressure or right ventricular hypertrophy.
| Ratio | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Change in Echocardiogram Parameters (RV/LV Ratio) | -0.6 (-0.6 to 0.3) |
ECHOs provide information regarding cardiac structure and function. Right atrial area was summarized at each time point listed.
| cm^2 | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Change in Echocardiogram Parameters (Right Atrial Area) | -2.88 (-15.8 to 5.3) |
ECHOs provide information regarding cardiac structure and function. RV diameter was summarized at each time point.
| mm | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Change in Echocardiogram Parameters (RV Diameter) | -2.61 (-16.6 to 18.8) |
ECHOs provide information regarding cardiac structure and function. RV free wall strain was summarized at each time point listed .
| percent | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Change in Echocardiogram Parameters (RV Free Wall Strain) | 1.28 (-8.2 to 15.4) |
ECHOs provide information regarding cardiac structure and function. RV myocardial performance index (MPI) was summarized at each time point listed. RV MPI is a measurement used to assess RV systolic function in patients with PH. MPI correlates with pulmonary arterial pressure. Normal MPI is approximately 0.35. Higher MPI values indicate higher pulmonary arterial pressure.
| MPI | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Change in Echocardiogram Parameters (RV Myocardial Performance Index) | -0.08 (-0.6 to 0.5) |
ECHOs provide information regarding cardiac structure and function. Tricuspid annular plane systolic excursion was summarized at each time point listed.
| mm | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Change in Echocardiogram Parameters (Tricuspid Annular Plane Systolic Excursion) | 1.20 (-5.0 to 7.8) |
PAH symptoms included fatigue, dyspnea, lower extremity edema, dizziness, syncope, chest pain, and orthopnea. Symptoms were scored (Grades 0 \[none\], 1 \[mild\], 2 \[moderate\], to 3 \[severe\]) except for syncope (0 \[No\], 1 \[Infrequent; 1 episode\], 2 \[Somewhat frequent; 2 to 3 episodes\], and 3 \[Often; \>4 episodes). A lower score was considered "improved"; a higher score was considered "worsened."
| Participants | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Fatigue — Improved | 11 |
| Fatigue — Worsened | 3 |
| Fatigue — No Change | 14 |
| Dyspnea — Improved | 17 |
| Dyspnea — Worsened | 1 |
| Dyspnea — No Change | 10 |
| Lower Extremity Edema — Improved | 8 |
| Lower Extremity Edema — Worsened | 4 |
| Lower Extremity Edema — No Change | 16 |
| Dizziness — Improved | 7 |
| Dizziness — Worsened | 4 |
| Dizziness — No Change | 17 |
| Syncope — Improved | 1 |
| Syncope — Worsened | 1 |
| Syncope — No Change | 26 |
| Chest Pain — Improved | 3 |
| Chest Pain — Worsened | 2 |
| Chest Pain — No Change | 23 |
| Orthopnea — Improved | 8 |
| Orthopnea — Worsened | 2 |
| Orthopnea — No Change | 18 |
The Health-related Quality of Life in Pulmonary Hypertension Questionnaire (emPHasis-10) is a 10-question questionnaire used during clinical assessments that measures quality of life by the patients participating in the study. The patients graded their response to each of the 10 health-related questions on a scale of 0 to 5 based on how they were feeling that day. The most favorable score for each question is 0, and the least favorable score for each question is 5. A total score was then summed for each subject based on their responses to the 10 questions. The lower the total score was (best possible total score was 0), the less living with PH was negatively affecting the quality of the patient's life. The higher the total score (worst possible score was 50), the more living with PH was negatively affecting the quality of the patient's life.
| score on a scale | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Change in Patient-reported Outcomes (Health-related Quality of Life) | -3.0 (-33 to 16) |
The Treatment Satisfaction Questionnaire for Medication (TSQM) is a 14-question questionnaire that measures the level of satisfaction or dissatisfaction patients have with their study medication in 4 areas: effectiveness (3 questions), side effects (5 questions), convenience (3 questions), and global satisfaction (3 questions). With the exception of the first side effects question (a yes or no question), all items have 5 or 7 responses which are scored from 1 (least satisfied) to 5 or 7 (most satisfied). A total score is then summed for each domain on the following scales: effectiveness 1-21, side effects 1-20, convenience 1-21, and global satisfaction 1-17. Lower total scores in each domain indicate dissatisfaction with the study medication and higher total scores indicate satisfaction.
| score on a scale | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Effectiveness | 4.76 (-28.6 to 42.9) |
| Side Effects | 5.00 (-50.0 to 35.0) |
| Convenience | -4.76 (-52.4 to 28.6) |
| Global Satisfaction | 0.00 (-47.1 to 35.3) |
6MWD low risk: \>440 m, intermediate risk: 165-440 m, high risk: \<165 m; NT-proBNP low risk: \<300 ng/L, intermediate risk: 300-1400 ng/L, high risk: \>1400 ng/L; WHO FC: low risk: I or II, intermediate risk: III, high risk: IV; and Right Atrial Area: low risk: \<18 cm², intermediate risk: 18-26 cm², high risk: \>26 cm². Moving from a higher risk category to a low risk category was considered "improved;" moving from a lower risk category to a higher risk category was considered "worsened."
| Participants | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| 6MWD — Improved | 4 |
| 6MWD — Worsened | 1 |
| 6MWD — No Change | 22 |
| NT-proBNP — Improved | 11 |
| NT-proBNP — Worsened | 1 |
| NT-proBNP — No Change | 16 |
| WHO FC — Improved | 11 |
| WHO FC — Worsened | 1 |
| WHO FC — No Change | 16 |
| Right Atrial Area — Improved | 8 |
| Right Atrial Area — Worsened | 1 |
| Right Atrial Area — No Change | 14 |
Low risk categories for the 4 selected parameters were: 6MWD \>440 m, serum NT-proBNP \<300 ng/L, WHO FC I or II, and right atrial area \<18cm². The rows of the table indicate the count of participants that were in the low risk category for the parameter at Week 16.
| Participants | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| 6MWD | 10 |
| NT-proBNP | 19 |
| WHO FC | 24 |
| Right Atrial Area | 14 |
The percentage of subjects that ended the study in achievement Class 1 (either achieved an Orenitram dose of ≥4 mg TID \[or TDD of 12 mg\] at Week 16 or a dose of ≥0.057 mg/kg TID \[or a TDD of 0.171 mg/kg\] for subjects \<70 kg), Class 2 (achieved a prescribed Orenitram dose ≥2 mg TID and \<4 mg TID \[or a TDD ≥6 mg and \<12 mg\] at specific visit, with at least 2 of the following 3 clinical parameters: 6MWD increase by ≥10% or ≥30 m from baseline, serum NT-proBNP reduction \>30% from baseline, or WHO FC I or II), or Class 3 (were not Class 1 or Class 2, or with class undetermined).
| Participants | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Class 1 | 23 |
| Class 2 | 2 |
| Class 3 | 4 |
The percentage of subjects that transitioned to oral treprostinil at any dose and were maintained on therapy at Week 16 (considered a "successful" result).
| Participants | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Transition and Maintenance of Orenitram Therapy | 28 |
Collected over Adverse events (AEs) were captured from when the subject signed the informed consent form until the subject completed the study or was withdrawn from the study, up to 20 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intravenous/Subcutaneous Treprostinil; Oral Treprostinil | 1/35 (2.9%) | 10/35 (28.6%) | 35/35 (100%) |
| Event | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Device dislocationProduct Issues | 2/35 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/35 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/35 |
| Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders | 1/35 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/35 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/35 |
| Right ventricular failureCardiac disorders | 1/35 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/35 |
| Bacterial sepsisInfections and infestations | 1/35 |
| EndocarditisInfections and infestations | 1/35 |
| Event | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| HeadacheNervous system disorders | 30/35 |
| NauseaGastrointestinal disorders | 25/35 |
| DiarrhoeaGastrointestinal disorders | 21/35 |
| FlushingVascular disorders | 20/35 |
| Pain in jawMusculoskeletal and connective tissue disorders | 18/35 |
| VomitingGastrointestinal disorders | 15/35 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 15/35 |
| FatigueGeneral disorders | 14/35 |
| Infusion site painGeneral disorders | 9/35 |
| PainGeneral disorders | 9/35 |
| Age, Continuous(years) | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Median | 56.0 (35 to 72) |
| Sex: Female, Male(Participants) | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Female | 24 |
| Male | 11 |
| Ethnicity (NIH/OMB)(Participants) | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 32 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 4 |
| White | 29 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| PAH Etiology(Participants) | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Idiopathic PAH | 15 |
| Associated with connective tissue disease | 9 |
| Associated with appetite suppressant or toxin use | 7 |
| Associated with HIV infection | 1 |
| Heritable PAH | 1 |
| Other | 2 |
| Associated with repaired congenital systemic-to-pulmonary shunts | 0 |
| Days Since Initial PAH Diagnosis(days) | Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
|---|---|
| Median | 245.0 (7 to 1959) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2019 to primary completion in May 2022, 39 months.
Results were first posted in Aug 2023, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil
Pulmonary Arterial Hypertension →